利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

338 条记录 (耗时 0.031 秒)

    DKK1 oncogene as therapeutic target for cancer and a diagnosing marker
    1.
    发明授权
    DKK1 oncogene as therapeutic target for cancer and a diagnosing marker 有权
    DKK1癌基因作为癌症治疗靶点和诊断标志物

    公开(公告)号：US08709731B2

    公开(公告)日：2014-04-29

    申请号：US12674660

    申请日：2008-08-21

    申请人： Yusuke Nakamura ,  Yataro Daigo ,  Shuichi Nakatsuru

    发明人： Yusuke Nakamura ,  Yataro Daigo ,  Shuichi Nakatsuru

    IPC分类号： G01N33/53

    CPC分类号： C07K16/32 ,  A61K2039/505 ,  C07K16/3046 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/574 ,  G01N2333/4703 ,  G01N2500/04 ,  G01N2800/50

    摘要： Described herein are antibodies and antibody fragments capable of treating or preventing cancers associated with the over-expression and/or up-regulation of DKK1. Also disclosed are methods of treating or preventing cancer using the antibody and methods and kits utilized to diagnosing cancer. The herein described products and methods find utility in the context of a variety of cancers, such as pancreatic cancer, gastric cancer, liver cancer, prostate cancer, breast cancer, cervical cancer, bile duct cancer, lung cancer and esophageal cancer.

    摘要翻译： 本文描述了能够治疗或预防与DKK1的过表达和/或上调相关的癌症的抗体和抗体片段。 还公开了使用抗体治疗或预防癌症的方法以及用于诊断癌症的方法和试剂盒。 本文描述的产品和方法在各种癌症如胰腺癌，胃癌，肝癌，前列腺癌，乳腺癌，子宫颈癌，胆管癌，肺癌和食管癌的情况下发现有用。

    OIP5 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
    2.
    发明申请
    OIP5 AS A TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS 审中-公开
    OIP5作为癌症治疗和诊断的目标基因

    公开(公告)号：US20110160288A1

    公开(公告)日：2011-06-30

    申请号：US13061105

    申请日：2009-08-24

    申请人： Yusuke Nakamura ,  Yataro Daigo ,  Akira Togashi

    发明人： Yusuke Nakamura ,  Yataro Daigo ,  Akira Togashi

    IPC分类号： A61K48/00 ,  C12Q1/68 ,  G01N33/574 ,  C07H21/00 ,  C07K16/32 ,  C07H21/04 ,  C12N15/63 ,  C12Q1/02 ,  A61P35/00

    CPC分类号： C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158

    摘要： The present invention relates to the roles played by OIP5 genes in lung and/or esophageal cancer carcinogenesis and features a method for treating and/or preventing lung and/or esophageal cancer by administering a double-stranded molecule against the OIP5 genes or a composition, vector or cell containing such a double-stranded molecule and antibody. The present invention also features methods for detecting and/or diagnosing lung and/or esophageal cancer, or assessing/determining the prognosis of and/or monitoring the efficacy of a cancer therapy in a patient with lung and/or esophageal cancer by detecting OIP5. Also, disclosed are methods of identifying compounds for treating and preventing cancer relating to OIP5.

    摘要翻译： 本发明涉及OIP5基因在肺和/或食道癌癌发生中的作用，其特征在于通过对OIP5基因或组合物施用双链分子来治疗和/或预防肺癌和/或食管癌的方法， 含有这种双链分子和抗体的载体或细胞。 本发明还涉及通过检测OIP5来检测和/或诊断肺和/或食管癌的方法，或评估/确定患有肺和/或食管癌患者的癌症治疗的预后和/或监测其功效的方法。 此外，公开了鉴定用于治疗和预防与OIP5有关的癌症的化合物的方法。

    Methods for treating lung cancers
    7.
    发明授权
    Methods for treating lung cancers 有权
    肺癌治疗方法

    公开(公告)号：US08138167B2

    公开(公告)日：2012-03-20

    申请号：US12278763

    申请日：2006-02-10

    申请人： Yusuke Nakamura ,  Yataro Daigo

    发明人： Yusuke Nakamura ,  Yataro Daigo

    IPC分类号： A01N43/00

    CPC分类号： G01N33/57423 ,  A61K31/47 ,  A61K31/517 ,  A61K31/519 ,  A61K31/5377 ,  A61K49/0004

    摘要： The present invention provided methods for treating lung cancers using therapeutic agents for lung cancers comprising erbB receptor inhibitors as active ingredients. Methods for examining the responsiveness of lung cancer patients to erbB receptor inhibitors by using blood amphiregulin (AREG) as an indicator were provided. Furthermore, methods for treating lung cancers in which responsiveness to an erbB receptor inhibitor is determined based on blood AREG concentration, and in which therapeutic agents are selectively administered to patients expected to be responsive, were also provided. Advanced therapeutic effects can be expected by administering an erbB receptor inhibitor to patients predicted to be responsive. The present invention contributes to the improvement of therapeutic effects of gefitinib (Product name: Iressa®) and such on lung cancers.

    摘要翻译： 本发明提供了使用包含erbB受体抑制剂作为活性成分的肺癌治疗剂治疗肺癌的方法。 提供了通过使用血液两性调节蛋白（AREG）作为指标来检查肺癌患者对erbB受体抑制剂的反应性的方法。 此外，还提供了治疗肺癌的方法，其中基于血液AREG浓度确定对erbB受体抑制剂的反应性，并且其中治疗剂被选择性地施用于预期具有反应性的患者。 通过对预测具有反应性的患者施用erbB受体抑制剂，可以预期先进的治疗效果。 本发明有助于改善吉非替尼（商品名：Iressa）等对肺癌的治疗效果。

    ECT2 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG AND ESOPHAGEAL CANCER
    9.
    发明申请
    ECT2 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG AND ESOPHAGEAL CANCER 审中-公开
    ECT2 ONCOGENE作为肺癌和食管癌的治疗目标和预防指标

    公开(公告)号：US20110319280A1

    公开(公告)日：2011-12-29

    申请号：US13002977

    申请日：2009-07-16

    申请人： Yusuke Nakamura ,  Yataro Daigo ,  Akira Togashi

    发明人： Yusuke Nakamura ,  Yataro Daigo ,  Akira Togashi

    IPC分类号： C40B30/04 ,  G01N33/566 ,  C12Q1/68 ,  G01N33/53

    CPC分类号： C12Q1/6886 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/57423 ,  G01N2800/50

    摘要： The invention features methods for detecting lung cancer or esophageal cancer, by detecting over-expression of ECT2 compared the normal organs. Also disclosed are methods of identifying compounds for treating and preventing lung cancer or esophageal cancer, based on the over-expression of ECT2 in the lung cancer or esophageal cancer, the cell proliferation function of ECT2. Also, provided are a method for treating lung cancer or esophageal cancer by administering a double-stranded molecule against the ECT2 gene or an antibody against ECT2 protein. The invention also provides products, including the double-stranded molecules and vectors encoding them, as well as compositions comprising the molecules or vectors, useful in the provided methods.

    摘要翻译： 本发明特征在于检测肺癌或食管癌的方法，通过检测ECT2与正常器官的过表达。 还公开了基于ECT2在肺癌或食管癌中的过表达，ECT2的细胞增殖功能，鉴定用于治疗和预防肺癌或食管癌的化合物的方法。 此外，提供了通过对ECT2基因施用双链分子或针对ECT2蛋白的抗体来治疗肺癌或食管癌的方法。 本发明还提供了包括双链分子和编码它们的载体的产物，以及可用于所提供的方法中的包含分子或载体的组合物。